Straits Times Index
3,316.56 -6.06 (-0.18%) Nikkei
38,646.11 -457.11 (-1.17%) Hang Seng
18,608.94 -259.77 (-1.38%) FTSE 100
8,317.59 -21.64 (-0.26%) Bitcoin USD
68,748.27 +1,389.58 (+2.06%) CMC Crypto 200
1,444.72 -23.38 (-1.59%)
AMGN Jun 2024 285.000 call
| Previous close | 28.90 |
| Open | 23.08 |
| Bid | 22.05 |
| Ask | 23.40 |
| Strike | 285.00 |
| Expiry date | 2024-06-21 |
| Day's range | 23.08 - 23.08 |
| Contract range | N/A |
| Volume | |
| Open interest | 46 |
ZacksThe Zacks Analyst Blog Highlights Apple, Mastercard, Amgen, Utah Medical Products and Bridger Aerospace
Apple, Mastercard, Amgen, Utah Medical Products and Bridger Aerospace are part of the Zacks top Analyst Blog.
ZacksTop Stock Reports for Apple, Mastercard & Amgen
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA) and Amgen (AMGN), as well as two micro-cap stocks Utah Medical Products, Inc. (UTMD) and Bridger Aerospace Group Holdings, Inc. (BAER).
BenzingaAmgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at
